FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892018897> ?p ?o ?g. }

• W2892018897 endingPage "150" @default.
• W2892018897 startingPage "140" @default.
• W2892018897 abstract "We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) enrolled 48 boys with Duchenne muscular dystrophy (4 to <7 years), with outcomes including clinical safety, pharmacokinetics and pharmacodynamic biomarkers. The study design included pharmacodynamic biomarkers in three contexts of use: 1. Secondary outcomes for pharmacodynamic safety (insulin resistance, adrenal suppression, bone turnover); 2. Exploratory outcomes for drug mechanism of action; 3. Exploratory outcomes for expanded pharmacodynamic safety. Vamorolone was safe and well-tolerated through the highest dose tested (6.0 mg/kg/day) and pharmacokinetics of vamorolone were similar to prednisolone. Using pharmacodynamic biomarkers, the study demonstrated improved safety of vamorolone versus glucocorticoids as shown by reduction of insulin resistance, beneficial changes in bone turnover (loss of increased bone resorption and decreased bone formation only at the highest dose level), and a reduction in adrenal suppression. Exploratory biomarkers of pharmacodynamic efficacy showed an anti-inflammatory mechanism of action and a beneficial effect on plasma membrane stability, as demonstrated by a dose-responsive decrease in serum creatine kinase activity. With an array of pre-selected biomarkers in multiple contexts of use, we demonstrate the development of the first dissociative steroid that preserves anti-inflammatory efficacy and decreases steroid-associated safety concerns. Ongoing extension studies offer the potential to bridge exploratory efficacy biomarkers to clinical outcomes." @default.
• W2892018897 created "2018-09-27" @default.
• W2892018897 creator A5000476303 @default.
• W2892018897 creator A5001301120 @default.
• W2892018897 creator A5012227405 @default.
• W2892018897 creator A5015437955 @default.
• W2892018897 creator A5016330600 @default.
• W2892018897 creator A5016501994 @default.
• W2892018897 creator A5017928129 @default.
• W2892018897 creator A5021901997 @default.
• W2892018897 creator A5024664136 @default.
• W2892018897 creator A5040044369 @default.
• W2892018897 creator A5040081755 @default.
• W2892018897 creator A5040374766 @default.
• W2892018897 creator A5042930850 @default.
• W2892018897 creator A5045978747 @default.
• W2892018897 creator A5049312380 @default.
• W2892018897 creator A5051207729 @default.
• W2892018897 creator A5053490218 @default.
• W2892018897 creator A5053586687 @default.
• W2892018897 creator A5061247977 @default.
• W2892018897 creator A5069968888 @default.
• W2892018897 creator A5070954626 @default.
• W2892018897 creator A5071163954 @default.
• W2892018897 creator A5072936660 @default.
• W2892018897 creator A5073404088 @default.
• W2892018897 creator A5073832610 @default.
• W2892018897 creator A5074721101 @default.
• W2892018897 creator A5081715473 @default.
• W2892018897 creator A5084459237 @default.
• W2892018897 creator A5085970575 @default.
• W2892018897 creator A5086644020 @default.
• W2892018897 creator A5088649964 @default.
• W2892018897 creator A5091023992 @default.
• W2892018897 date "2018-10-01" @default.
• W2892018897 modified "2023-10-01" @default.
• W2892018897 title "Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug" @default.
• W2892018897 cites W1622083158 @default.
• W2892018897 cites W1968854849 @default.
• W2892018897 cites W1974487938 @default.
• W2892018897 cites W1994387933 @default.
• W2892018897 cites W1999638106 @default.
• W2892018897 cites W2001880579 @default.
• W2892018897 cites W2007623619 @default.
• W2892018897 cites W2007660314 @default.
• W2892018897 cites W2010042253 @default.
• W2892018897 cites W2019927301 @default.
• W2892018897 cites W2044274662 @default.
• W2892018897 cites W2064431078 @default.
• W2892018897 cites W2068461287 @default.
• W2892018897 cites W2086485710 @default.
• W2892018897 cites W2087793245 @default.
• W2892018897 cites W2096964097 @default.
• W2892018897 cites W2101209989 @default.
• W2892018897 cites W2116279332 @default.
• W2892018897 cites W2119948136 @default.
• W2892018897 cites W2123070528 @default.
• W2892018897 cites W2130353405 @default.
• W2892018897 cites W2140141598 @default.
• W2892018897 cites W2155487985 @default.
• W2892018897 cites W2177839715 @default.
• W2892018897 cites W2418817496 @default.
• W2892018897 cites W2472323562 @default.
• W2892018897 cites W2517949748 @default.
• W2892018897 cites W2518245700 @default.
• W2892018897 cites W2520166953 @default.
• W2892018897 cites W2530334099 @default.
• W2892018897 cites W2532141188 @default.
• W2892018897 cites W2558318757 @default.
• W2892018897 cites W2604524922 @default.
• W2892018897 cites W2763834661 @default.
• W2892018897 cites W2770733887 @default.
• W2892018897 cites W2784992484 @default.
• W2892018897 cites W2792574008 @default.
• W2892018897 cites W2796206050 @default.
• W2892018897 cites W2807412594 @default.
• W2892018897 cites W2888844281 @default.
• W2892018897 doi "https://doi.org/10.1016/j.phrs.2018.09.007" @default.
• W2892018897 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6218284" @default.
• W2892018897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30219580" @default.
• W2892018897 hasPublicationYear "2018" @default.
• W2892018897 type Work @default.
• W2892018897 sameAs 2892018897 @default.
• W2892018897 citedByCount "58" @default.
• W2892018897 countsByYear W28920188972018 @default.
• W2892018897 countsByYear W28920188972019 @default.
• W2892018897 countsByYear W28920188972020 @default.
• W2892018897 countsByYear W28920188972021 @default.
• W2892018897 countsByYear W28920188972022 @default.
• W2892018897 countsByYear W28920188972023 @default.
• W2892018897 crossrefType "journal-article" @default.
• W2892018897 hasAuthorship W2892018897A5000476303 @default.
• W2892018897 hasAuthorship W2892018897A5001301120 @default.
• W2892018897 hasAuthorship W2892018897A5012227405 @default.
• W2892018897 hasAuthorship W2892018897A5015437955 @default.
• W2892018897 hasAuthorship W2892018897A5016330600 @default.
• W2892018897 hasAuthorship W2892018897A5016501994 @default.
• W2892018897 hasAuthorship W2892018897A5017928129 @default.

• next